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Selective CDK9 inhibition overcomes TRAIL resistance
by concomitant suppression of cFlip and Mcl-1
J Lemke1,2, S von Karstedt1, M Abd El Hay1, A Conti1,3, F Arce4, A Montinaro1, K Papenfuss1, MA El-Bahrawy5 and H Walczak*,1
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing
toxicity in vivo. However, to date, TRAIL-receptor agonists have only shown limited therapeutic benefit in clinical trials. This can,
most likely, be attributed to the fact that 50% of all cancer cell lines and most primary human cancers are TRAIL resistant.
Consequently, future TRAIL-based therapies will require the addition of sensitizing agents that remove crucial blocks in the
TRAIL apoptosis pathway. Here, we identify PIK-75, a small molecule inhibitor of the p110a isoform of phosphoinositide-3 kinase
(PI3K), as an exceptionally potent TRAIL apoptosis sensitizer. Surprisingly, PI3K inhibition was not responsible for this activity.
A kinome-wide in vitro screen revealed that PIK-75 strongly inhibits a panel of 27 kinases in addition to p110a. Within this panel,
we identified cyclin-dependent kinase 9 (CDK9) as responsible for TRAIL resistance of cancer cells. Combination of CDK9
inhibition with TRAIL effectively induced apoptosis even in highly TRAIL-resistant cancer cells. Mechanistically, CDK9 inhibition
resulted in downregulation of cellular FLICE-like inhibitory protein (cFlip) and Mcl-1 at both the mRNA and protein levels.
Concomitant cFlip and Mcl-1 downregulation was required and sufficient for TRAIL sensitization by CDK9 inhibition. When
evaluating cancer selectivity of TRAIL combined with SNS-032, the most selective and clinically used inhibitor of CDK9, we found
that a panel of mostly TRAIL-resistant non-small cell lung cancer cell lines was readily killed, even at low concentrations of
TRAIL. Primary human hepatocytes did not succumb to the same treatment regime, defining a therapeutic window. Importantly,
TRAIL in combination with SNS-032 eradicated established, orthotopic lung cancer xenografts in vivo. Based on the high
potency of CDK9 inhibition as a cancer cell-selective TRAIL-sensitizing strategy, we envisage the development of new, highly
effective cancer therapies.
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Introduction
De novo and acquired resistance to conventional chemother-
apy remains the major obstacle in treating many cancers
today. Intrinsic apoptosis resistance of cancer cells often
involves disabling of the intrinsic apoptotic machinery.1
Therefore, targeting cancer cells via the extrinsic cell death
machinery involving death receptors of the tumor necrosis
factor (TNF) superfamily has become an attractive approach
in cancer research. However, attempts to use cell death-
inducing CD95L or TNF for systemic therapy were hampered
by severe toxicity.2,3 In contrast, TNF-related apoptosis-
inducing ligand (TRAIL) can induce apoptosis selectively in
tumor cells in vitro and in vivo.4,5
Based on these findings, TRAIL-receptor (TRAIL-R) ago-
nists, comprising recombinant soluble TRAIL and agonistic
TRAIL-R antibodies, are currently evaluated in clinical trials.
However, so far these trials only showed very limited
therapeutic benefit.6 It has emerged that, although TRAIL is
capable of inducing apoptosis in many cancer cell lines in vitro
and in vivo, about 50% of cancer cell lines and the majority of
primary tumor cells are TRAIL resistant.7 The limited success
of clinical trials conducted so far is likely to be attributable to
this fact. However, combinatorial treatment with sensitizing
agents can break TRAIL apoptosis resistance resulting in
synergistic and selective killing of tumor cells.4 These
findings have encouraged extensive research into identifying
potent TRAIL-sensitizing agents that do not sensitize non-
transformed cells.
Binding of TRAIL to cognate apoptosis-inducing TRAIL-R1
(DR4)8 and/or TRAIL-R2 (DR5)9 results in receptor trimeriza-
tion. The adaptor protein FAS-associated protein with death
domain (FADD) is recruited to the death domain (DD) of
trimerized TRAIL-Rs and, in turn, enables caspase-8 and -10
recruitment to and activation at the death-inducing signaling
complex (DISC).10–14 In type-I cells, activation of caspase-8
and -10 at the DISC results in sufficient activation of the
effector caspase-3, ultimately resulting in apoptosis. In type-II
1Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK; 2Clinic of General and
Visceral Surgery, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; 3Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS
Istituto Nazionale dei Tumori, 20133 Milan, Italy; 4Cancer Immunology Unit, University College London, 72 Huntley Street, London WC1E 6DD, UK and 5Department of
Histopathology, Imperial College London, Du Cane Road, London W12 0NN, UK
*Corresponding author: H Walczak, Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD,
UK. Tel: +44 207 67946471; Fax: +44 207 679 6925; E-mail: h.walczak@ucl.ac.uk
Received 29.6.13; revised 07.10.13; accepted 05.11.13; Edited by T Mak; published online 20.12.13
Keywords: CDK9; TRAIL; NSCLC; PIK-75; SNS-032
Abbreviations: AST, aspartate transaminase; CDK, cyclin-dependent kinase; cFlip, cellular FLICE-like inhibitory protein; DD, death domain; DISC, death-inducing
signaling complex; FADD, Fas-associated protein with death domain; IAP, inhibitor of apoptosis proteins; NSCLC, non-small cell lung cancer; PI3K, phosphoinositide-3
kinase; PHH, primary human hepatocytes; P-TEFb, positive transcription elongation factor b; RNA Pol II, RNA-polymerase II; TNF, tumor necrosis factor; TRAIL, tumor
necrosis factor-related apoptosis-inducing ligand; WT, wild-type; XIAP, X-linked inhibitor of apoptosis
Cell Death and Differentiation (2014) 21, 491–502
& 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14
www.nature.com/cdd
cells, additional activation of the mitochondrial pathway is
required to neutralize X-linked inhibitor of apoptosis protein
(XIAP)-mediated effector caspase inhibition via release of
Smac/DIABLO from mitochondria.15
In order to prevent excessive apoptosis induction by TRAIL,
several mechanisms that negatively regulate the TRAIL
apoptosis pathway have evolved that are frequently exacer-
bated by cancer cells. The cellular FLICE-like inhibitory
protein (cFlip) competes with caspase-8 for binding to FADD,
thereby preventing caspase-8 activation and, consequently,
apoptosis induction.16 Other cellular factors that antagonize
apoptosis induction by TRAIL include the inhibitor of apoptosis
proteins (IAPs).17 Among these, XIAP has been shown to
have a major role in mediating resistance to TRAIL-induced
apoptosis.18 In type-II cells, resistance to TRAIL-induced
apoptosis can be mediated by high expression of anti-
apoptotic Bcl-2 family members such as Bcl-2, Bcl-xL and
Mcl-1 that antagonize truncated Bid-triggered Bax/Bak-
mediated mitochondrial outer membrane permeabilization
and the consequent release of the pro-apoptotic factors
cytochrome c and Smac/DIABLO.19
Kinase inhibitors have emerged as a novel class of targeted
small molecule agents with great therapeutic potential in
cancer treatment. This is owed to the fact that kinases are
crucial components of most cellular signaling pathways that
promote tumor cell survival, growth, migration, invasion and
metastasis. Several inhibitors of the phosphoinositide-3
kinase (PI3K) pathway are currently in clinical trials20 and,
interestingly, pan-PI3K inhibitors, inhibiting all four catalytic
isoforms (p110a, b, g and d), have been shown to sensitize to
TRAIL-induced apoptosis.21,22 Activating mutations of the
a-isoform of PI3K (p110a) occur with frequencies of up to 30%
in cancer23 and, recently, mutated p110a was suggested to
render cancer cell lines resistant to TRAIL-induced apopto-
sis.24 Therefore, we set out to test whether specific inhibition
of p110a would render cancer cells sensitive to TRAIL-
induced apoptosis.
Results
The p110a inhibitor PIK-75 potently sensitizes tumor
cells to TRAIL-induced apoptosis independently of PI3K
inhibition. To investigate whether inhibition of one of the
PI3K isoforms is sufficient to sensitize cancer cells to TRAIL-
induced apoptosis, we treated HeLa cells with TRAIL in the
presence or absence of pharmacological inhibitors that have
been reported to be isoform specific (PIK-75 (p110a), TGX-
221 (p110b), AS-252424 (p110g) and IC-87114 (p110d)) (for
IC50 values see Supplementary Figure S1a). Whereas
co-treatment with inhibitors of the b-, g- and d-isoforms of
PI3K showed only marginal effects, co-treatment with PIK-75
profoundly increased TRAIL sensitivity of HeLa cells shifting
the sensitivity of these cells by 3–4 orders of magnitude
(Figure 1a and Supplementary Figure S1b). HeLa cells are
sensitive to higher concentrations of TRAIL; however, many
other cancer cell lines and most primary cancer cells are
TRAIL resistant.7 Therefore, we next tested whether the
exceptionally potent TRAIL sensitization exerted by PIK-75 in
HeLa cells would translate into sensitization of the highly
TRAIL resistant non-small cell lung cancer (NSCLC) cell line
A549. Indeed, when treated with PIK-75 A549 cells became
sensitive to apoptosis induction by TRAIL, even at concentra-
tions of TRAIL as low as 10ng/ml (Supplementary Figure S1c).
Intriguingly, when examining clonogenic survival, we
observed that this novel combination almost completely
obliterated clonogenic survival of A549 cells (Figure 1b).
Having shown that PIK-75, a potent inhibitor of p110a, is a
very effective TRAIL sensitizer, we next investigated whether
specific inhibition of the p110a isoform of PI3K was capable of
breaking TRAIL resistance in cancer cells and, hence,
responsible for the PIK-75-mediated effect. To this end, we
performed RNAi-mediated silencing of p110a as compared to
p110b and DNA-PK, which has been shown to be inhibited by
PIK-75 in addition to p110a.25 Surprisingly, silencing of p110a,
p110b and DNA-PK, or any combination thereof, did not
sensitize HeLa cells to TRAIL-induced apoptosis (Figure 1c,
knockdown efficiency in Supplementary Figure S1d). In order
to test the possibility that very low amounts of protein
remaining after knockdown may be sufficient to maintain
resistance, we also used two pan-PI3K inhibitors, GDC-0941
and BEZ-235, which both inhibit p110a with even lower IC50s
than PIK-75.26,27 In addition, we also used A66, a novel
p110a-specific inhibitor28 (for IC50 values see Supplementary
Figure S1e). However, when testing these three compounds,
we found that none of them reproduced the extent of
sensitization observed with PIK-75 co-treatment (Figure 1d).
Interestingly, BEZ-235 was more efficient than PIK-75 at
suppressing PI3K activity as assessed by phosphorylation of
AKT (Supplementary Figure S1f). Moreover, concentrations of
up to 10 mM of A66 were not able to suppress pan-PI3K
activity in HeLa cells, which have been reported to harbor wild-
type (WT) PI3K p110a (Supplementary Figure S1f). This is in
line with a recent report that selective inhibition of p110a using
A66 is only efficient in preventing phosphorylation of AKT in
cells with activating mutations in p110a.28
These results were unexpected but led us to conclude that
PIK-75 sensitizes cancer cells to TRAIL-induced apoptosis
either independently of p110a or by inhibiting p110a and (an)
additional kinase(s). We therefore used PIK-75 in an in vitro
screen testing its capability to inhibit a panel of 451 kinases
(80% of the kinome). This revealed that, in addition to p110a,
PIK-75 potently inhibited 27 other kinases when used at
200 nM (Figure 1e), a concentration at which it effectively
sensitizes cancer cells to TRAIL. In conclusion, we estab-
lished that PIK-75 potently breaks TRAIL resistance, but its
p110a-inhibitory activity is either not responsible or alone not
sufficient to sensitize cancer cells to TRAIL.
CDK9 is the PIK-75-target responsible for TRAIL
sensitization. To evaluate which of the 27 kinases inhibited,
or which combination thereof, was responsible for PIK-75-
mediated sensitization to TRAIL-induced apoptosis, we
screened all 27 kinases identified in the in vitro screen by
siRNA knockdown for sensitization to TRAIL (Supplementary
Figure S2a). Knockdown of 26 of these kinases did not affect
sensitivity to TRAIL. Silencing of cyclin-dependent kinase 9
(CDK9), however, potently sensitized HeLa and A549 cells to
TRAIL-induced apoptosis (Figures 2a and b). CDK9 is a
member of the family of CDKs, which are mainly known for
their function in cell cycle regulation.29 Recently, it was
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shown that a subset of CDKs, namely CDK7 and CDK9
regulate transcription.30,31 Our screen revealed that
PIK-75 also inhibits CDK7. However, a role of CDK7 in
mediating TRAIL resistance could be excluded, as CDK7
knockdown did not sensitize to TRAIL-induced apoptosis
(Figures 2a and b). Moreover, a contributing role of the most
prominent members of the cell cycle-regulating CDKs,
CDK1, 2, 4 and 6 could also be excluded by knockdown
experiments (Supplementary Figures S2b and c).
CDK9 inhibition by SNS-032 potently sensitizes to
TRAIL-induced apoptosis. Several CDK inhibitors targeting
different subsets of CDKs are currently evaluated in clinical
trials.32 Among them, SNS-032 (BMS-387032) appears to be
the most selective CDK9 inhibitor. It inhibits CDK2, CDK7
and CDK9 selectively over other CDKs and kinases, but
its inhibitory capacity is about 10-fold selective for CDK9
(IC50¼ 4 nM) over CDK2 (IC50¼ 38 nM) and 15-fold over
CDK7 (IC50¼ 62 nM).33 CDK9, in a complex with its partner
Cyclin-T/K, constitutes the positive transcription elongation
factor b (P-TEFb) that promotes transcriptional elongation by
phosphorylation of substrates.34,35 The most important
substrate of P-TEFb is the carboxy-terminal domain of
RNA-polymerase II (RNA-Pol II), which is phosphorylated
by CDK9 at Ser-2. Analysis of Ser-2 phosphorylation of
RNA-Pol II showed that PIK-75 and SNS-032 exerted similar
inhibitory activity towards CDK9 (Supplementary Figure
S3a). We next evaluated a novel combinatorial therapy
consisting of the clinically used CDK9 inhibitor SNS-032 and
TRAIL. Indeed, SNS-032 markedly sensitized HeLa
and A549 cells to TRAIL-induced cell death (Figure 3a).
Sensitized cells died apoptotically (Figure 3b) and this cell
DMSO
izTRAIL [ng/ml] 0 10 100
HeLa
0
20
40
60
80
100
DMSO
PIK-75 [100nM]
A66 [10μM]
BEZ-235 [200nM]
GDC-0941 [200nM]V
ia
bi
lit
y 
[%
]
HeLa
0
20
40
60
80
100
0.1 101 100 1000
si-Ctr l
si-DNA-PK
si-p110α
si-p110β
si-DNA-PK / si-p110α
si-DNA-PK / si-p110β
izTRAIL [ng/ml]
Vi
ab
ili
ty
 [%
]
0 0.1 101 100 1000
izTRAIL [ng/ml]
0
Kinase % Ctrl Kinase % Ctrl
CDK7 2 JAK3 0
CDK9 6 LATS2 8
CDK14 9 MAP4K2 4
CLK1 1 MET 3
6
0
CLK2 2 PIK3CA
CLK3 2 PIK3CG
CLK4 1
8
PKAalpha 3
7
0
4
3
CK2A2 PKAbeta
DYRK1A 0 PKCepsilon
DYRK1B 1 PKCtheta
ERK8 2 PKCeta
FLT3 1
9
4
PHKG1 9
5HIPK1 PKN1
HIPK2 YSK4 0
JAK2 6
HeLa
0
20
40
60
80
100
0.1 101 100 1000
DMSO
PIK-75 [100nM]
TGX-221 [1μM]
AS-252424 [1μM]
0
IC-87144 [1μM]
izTRAIL [ng/ml]
Vi
ab
ili
ty
 [%
]
PIK-75
[200nM]
Figure 1 PIK-75 profoundly sensitizes cancer cells to TRAIL-induced apoptosis independently of PI3K inhibition. (a) HeLa cells were preincubated for 1 h with the
indicated PI3K inhibitors and subsequently stimulated with izTRAIL at the indicated concentrations. Cell viability was quantified after 24 h. (b) A549 cells were treated with
DMSO or PIK-75 (200 nM) for 1 h and subsequently stimulated with izTRAIL for 24 h. Long-term survival was visualized after 7 days by crystal violet staining. One of two
independent experiments is shown. (c) HeLa cells were transfected with the indicated siRNAs. After 48 h, cells were stimulated with izTRAIL at different concentrations. Cell
viability was analyzed 24 h later. (d) HeLa cells were preincubated for 1 h with the different PI3K inhibitors at the indicated concentrations and subsequently stimulated with
izTRAIL at different concentrations. Cell viability was quantified after 24 h. (e) The capacity of PIK-75 at 200 nM to bind to a panel of 451 human kinases was determined by
analyzing the binding interaction (%) compared with DMSO (¼ 100%) using Kinomescan. Hits (o10% remaining activity) are visualized (red circles) and listed in the table.
Values (a, c and d) are means±S.E.M. of three independent experiments
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death was prevented by the caspase-inhibitor zVAD (Supple
mentary Figure S3b). Finally, SNS-032 in combination with
TRAIL almost completely abrogated clonogenic survival of
A549 cells (Figure 3c). These data demonstrate that
cancer cell lines can be strongly sensitized to TRAIL-
induced apoptosis via CDK9 inhibition using SNS-032, a
small molecule inhibitor that is already undergoing clinical
testing.
In line with these findings, cancer cells treated with TRAIL in
the presence of SNS-032 showed a drastic increase in the
cleavage of caspase-8, Bid, caspase-9, -3 and poly ADP
ribose polymerase (PARP) (Figure 3d and Supplementary
Figure S3c). Moreover, cells in which CDK9 was silenced
using siRNA also showed increased activation of the apoptotic
caspase cascade (Supplementary Figure S3d). As expected
from this finding, DISC analysis upon CDK9 inhibition using
SNS-032 (Figure 3e) or upon CDK9 knockdown
(Supplementary Figure S3e) revealed that caspase-8
cleavage generating the p18 fragment was enhanced upon
CDK9 inhibition or suppression at the DISC (Figure 3e,
Supplementary Figure S3e). Thus, CDK9 inhibition facilitates
initiation of the caspase cascade at the DISC as part of its
sensitization mechanism.
CDK9 mediates TRAIL resistance by promoting
concomitant transcription of cFlip and Mcl-1. Having
established that CDK9 inhibition efficiently sensitizes cancer
cell lines to TRAIL-induced apoptosis, we next addressed
which molecular changes are responsible for this effect.
Upregulation of TRAIL-R1 and/or TRAIL-R2 often correlates
with, and sometimes also contributes to, TRAIL apoptosis
sensitization.36 However, treatment of HeLa or A549 cells
with PIK-75 or SNS-032 did not alter TRAIL-R1/R2 surface
expression (Figure 4a), in line with similar recruitment of
TRAIL-R1/2 in the DISC analysis (Figure 3e). Consequently,
TRAIL sensitization by CDK9 inhibition is likely to require
changes in intracellular modulators of the TRAIL apoptosis
pathway that should enhance DISC activity and possibly
additional downstream steps in the pathway. We, therefore,
next investigated whether known components of the TRAIL–
DISC and the downstream apoptosis pathway it activates are
regulated by PIK-75 or SNS-032 treatment. Whereas the
majority of the DISC components and downstream pro- and
anti-apoptotic proteins remained unchanged, cFlip and Mcl-1
protein levels were rapidly suppressed by pharmacological
CDK9 inhibition by SNS-032 or PIK-75 (Figure 4b and
Supplementary Figure S4a). Because siRNA-mediated
suppression of CDK9, performed in the presence or absence
of pan-caspase inhibition to exclude a possible impact of
CDK9-silencing-induced apoptosis, also resulted in down-
regulation of cFlip and Mcl-1, we can conclude that CDK9 is
required to maintain high expression of these anti-apoptotic
proteins in cancer cells (Figure 4c).
CDK9 is known for its role in transcriptional elongation,
suggesting that the observed downregulation of cFlip and
Mcl-1 protein levels could be caused by suppression of their
transcripts. In line with this hypothesis, SNS-032 treatment
rapidly decreased the amount of mRNA for cFlip and Mcl-1
(Figure 4d). The effect was a consequence of direct inhibition
of transcription, because co-treatment with SNS-032 and the
transcriptional inhibitor actinomycin D37 did not further reduce
mRNA levels (Supplementary Figure S4b). Moreover,
preincubation with the translational inhibitor cycloheximide
before SNS-032 treatment did not inhibit SNS-032-mediated
mRNA suppression (Supplementary Figure S4b). Co-incubation
with actinomycin D and cycloheximide induced a steady-state
level of mRNA. Additional treatment with SNS-032 did not
reduce Mcl-1 mRNA, showing that SNS-032 does not induce
degradation of mRNA. Next, we analyzed cFlip and Mcl-1
mRNA upon CDK9 knockdown. In slight contrast to CDK9
inhibition using SNS-032, prolonged silencing of CDK9 using
siRNA also strongly affected mRNA levels of housekeeping
genes. Therefore, we normalized mRNA amounts to cell
numbers used for RNA extraction. The amplification of cFlip
and Mcl-1 transcripts by real-time PCR (RT-PCR) required a
higher cycle threshold, demonstrating that their transcripts are
indeed suppressed when normalized to the cell number
(Supplementary Figure S4c). We conclude that SNS-032-
induced suppression of cFlip and Mcl-1 is mediated by
direct inhibition of global transcription that will preferentially
affect expression levels of short-lived proteins such as
cFlip and Mcl-1.
Concomitant downregulation of cFlip and Mcl-1 is
sufficient and required for CDK9 inhibition-induced
TRAIL sensitization. To evaluate whether concomitant
suppression of cFlip and Mcl-1 was sufficient for CDK9
inhibition-mediated TRAIL sensitization, we silenced cFlip
and/or Mcl-1 in HeLa and A549 cells. Hela cells were
sensitized to die by Mcl-1 knockdown alone only when high
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Figure 2 CDK9 is the PIK-75-target that is responsible for TRAIL sensitization.
HeLa (a) or A549 cells (b) were transiently transfected with the indicated siRNAs for
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Cell viability was determined 24 h later. Representative western blots of knockdown
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concentrations of TRAIL were used. Knockdown of cFlip, in
turn, sensitized at lower TRAIL concentrations, whereas at
higher TRAIL concentrations HeLa cells were rendered more
resistant by cFlip knockdown (Figure 5a). The latter may be
attributable to the interesting observation that knockdown of
cFlip brought about the upregulation of Mcl-1. In A549 cells,
silencing of neither cFlip nor Mcl-1 alone was sufficient to
sensitize to TRAIL-induced apoptosis (Figure 5b). Combined
knockdown of both components, however, resulted in a
striking synergistic sensitization rendering both, HeLa and
A549 cells, highly susceptible to TRAIL-induced apoptosis
(Figures 5a and b). Thus, combined downregulation of cFlip
and Mcl-1 is sufficient to break TRAIL resistance.
To further investigate the interesting observation that
silencing of either cFlip or Mcl-1 resulted in the inverse
upregulation of the respective other protein, we also analyzed
transcripts of cFlip and Mcl-1 upon knockdown. Silencing of
cFlip, Mcl-1 or the combination thereof resulted in comparable
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Figure 3 CDK9 inhibition by SNS-032 potently synergizes with TRAIL to kill cancer cells. (a) HeLa and A549 cells were preincubated with DMSO or SNS-032 (300 nM) for
1 h and subsequently stimulated with izTRAIL at the concentrations indicated. Cell viability was determined after 24 h. (b) A549 cells were preincubated with DMSO or
SNS-032 (300 nM) for 1 h and subsequently stimulated with indicated concentrations of izTRAIL. Apoptosis was determined after 24 h. (c) A549 cells were treated with DMSO
or SNS-032 (300 nM) for 1 h and subsequently stimulated for 24 h with izTRAIL (10 or 100 ng/ml). Long-term survival was visualized after 7 days by crystal violet staining. One
of two independent experiments is shown. (d) A549 cells were preincubated with DMSO or SNS-032 (300 nM) for 4 h and subsequently stimulated with izTRAIL (100 ng/ml) for
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and efficient suppression of the respectively targeted tran-
scripts (Supplementary Figure S5a). Interestingly, the inverse
upregulation we observed on the protein level was also
apparent on the transcriptional level (Supplementary Figure
S5a), suggesting that this phenomenon is, at least partially,
regulated on the transcriptional level.
To test whether cFlip and/or Mcl-1 were responsible for the
block of TRAIL-induced apoptosis that is specifically removed
by CDK9 inhibition, we overexpressed cFlip and/or Mcl-1 in
HeLa cells before treatment with SNS-032 and TRAIL.
Transfection was highly efficient (Supplementary Figure
S5b) and nontoxic to the cells (Supplementary Figure S5c).
Overexpression of cFlip or Mcl-1 alone rendered these cells
slightly more TRAIL resistant but could only marginally inhibit
SNS-032-mediated sensitization (Figure 5c). Combined over-
expression, however, rendered HeLa cells almost completely
resistant to TRAIL-induced apoptosis and prevented SNS-
032-mediated sensitization (Figure 5c). Thus, SNS-032
sensitizes cancer cell lines to TRAIL-induced apoptosis by
concomitant suppression of cFlip and Mcl-1.
We next investigated whether CDK9 inhibition-induced
TRAIL sensitization requires activation of the mitochondrial
pathway. To do so, we used the isogenic HCT-116 colon
carcinoma cell lines in which Bax and Bak are either both
expressed (parental HCT-116 WT cells) or both genetically
deleted (BAX/BAK-deficient HCT-116 cells). HCT-116 WT
cells were partially TRAIL sensitive but profoundly sensitized
by co-treatment with SNS-032 (Supplementary Figure S5d).
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Figure 4 CDK9 mediates TRAIL resistance by promoting concomitant transcription of cFlip and Mcl-1. (a) A549 or HeLa cells were incubated with SNS-032 (300 nM) or
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Their Bax/Bak-deficient counterparts, however, were com-
pletely resistant to SNS-032-mediated TRAIL sensitization.
Thus, TRAIL sensitizationmediated by CDK9 inhibition uses a
type-II apoptosis pathway that requires both, effective DISC-
mediated caspase-8 activation with consequent Bid cleavage,
enabled by cFlip downregulation, and efficient triggering of the
mitochondrial apoptosis pathway by cleaved Bid, enabled by
Mcl-1 downregulation.
Combined CDK9 inhibition and TRAIL selectively kills
NSCLC cell lines but not primary human hepatocytes
within a therapeutic window. On all cancer cell lines
tested, including primarily TRAIL-resistant A549 cells,
already low concentrations of TRAIL (1–10 ng/ml) in the
presence of SNS-032 (300 nM) were sufficient to reach
maximum efficiency in killing these cells. To investigate
whether this was a coincidence or may be applicable
more broadly, we extended our study to an established
panel of NSCLC cell lines.38 This panel includes cells
that are mutated in KRAS and/or p53 (Supplementary
Figure S6a). The majority of the cell lines were TRAIL
resistant, resembling TRAIL sensitivity of primary cancer
cells (Figure 6a and Supplementary Figure S6b). However,
all cell lines tested were potently sensitized to 10 ng/ml of
TRAIL by co-treatment with SNS-032 at 300 nM, irrespective
of their oncogenic mutations (Figure 6a and Supplementary
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Figure S6b). Thus, SNS-032/TRAIL co-treatment enables
efficient killing in a broad range of cancer cell lines,
irrespective of their p53-status.
Considering the remarkable sensitization observed with
combination of TRAIL and SNS-032, we next tested the
cancer selectiveness of this new combination. Hepatotoxicity
is a major concern for the clinical application of novel cancer
therapeutics and special care should be taken in the
development of therapies containing TNF superfamily
members.3 We therefore next assessed the effect of TRAIL
and/or SNS-032 treatment on primary human hepatocytes
(PHH). In line with our previous results,39 the recombinant
form of TRAIL used in our study (izTRAIL) did not reduce
viability of PHH (Figure 6b). In contrast, PHH were readily
killed by recombinant CD95L that served as a control (Figure 6c).
Treatment of PHH with SNS-032 at 300 nM in combination
with TRAIL used at different concentrations revealed that at
high concentrations of TRAIL (100 ng/ml and 1000ng/ml)
hepatocytes died when co-treated with SNS-032 (Figure 6b).
However, co-treatment with SNS-032 at 300 nM and TRAIL at
10 ng/ml, the concentrations at which these drugs were highly
efficient at killing cancer cells when combined, did not affect
viability of hepatocytes. The same nontoxic window was
confirmed for the levels of aspartate transaminase (AST),
which is released when liver cells are damaged (Figure 6d),
and the levels of caspase-cleaved cytokeratin 18 (Figure 6e).
Therefore, our novel therapeutic combination can be applied
within a considerable therapeutic window. At the same time,
toxicity would be expected at higher levels of TRAIL.
TRAIL combined with CDK9 inhibition eradicates
established orthotopic lung tumors. Having established
an applicable therapeutic window for our newly identified
combination of TRAIL with SNS-032 in vitro, we next
assessed this combination’s potency in an orthotopic model
of lung cancer in vivo. To this end, we induced lung tumors
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via tail vein injection of A549 cells stably expressing
luciferase (A549-luc). After 7 days, mice were randomized
to create treatment groups of mice with comparable tumor
burden in each group (Supplementary Figure S7). Subse-
quently, a 4-day treatment regime was started with either
vehicle, TRAIL, SNS-032 or the combination of SNS-032 and
TRAIL (Figure 7a). Whereas TRAIL treatment alone had a
slight growth inhibitory effect, and SNS-032 only marginally
affected lung tumor burden, combined treatment with TRAIL
and SNS-032 induced a drastic antitumor effect. TRAIL/SNS-
032 treatment completely eradicated established lung tumors
in most mice, as determined by in vivo bioluminescence
imaging (Figure 7b) and subsequent histopathological
inspection of lung sections (Figure 7c). Strikingly, and in line
with the bioluminescence data, seven out of eight mice that
had received TRAIL combined with SNS-032 were histolo-
gically tumor free after a 4-day treatment cycle.
Discussion
We found that the supposedly p110a-specific inhibitor PIK-75
potently sensitizes to TRAIL-induced apoptosis. Surprisingly,
however, PI3K inhibition was not responsible for this effect. A
kinome-wide screen revealed that PIK-75 strongly inhibits 27
kinases in addition to p110a. Off-target activity is a common
feature among kinase inhibitors, as most inhibitors are ATP-
competitive compounds and the ATP-binding pocket is highly
conserved among the human kinome.40,41 We show that
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PIK-75 exerts off-target effects toward CDK7 and CDK9. This
is in line with a recent report on the effects of PIK-75 on acute
myeloid leukemia.42 Moreover, we demonstrate that PIK-75’s
activity to sensitize cancer cells to TRAIL-induced apoptosis is
exclusively due to inhibition of CDK9. CDKs are mainly known
for their regulatory role in cell cycle, and development of CDK
inhibitors for cancer therapy is aimed at suppressing exacer-
bated cell cycle progression.43 Recently, a subset of CDKs,
namely CDK7 and CDK9, has been implicated in regulating
transcription.30,31 CDK9 inhibition has been shown to block
transcriptional elongation, thereby suppressing expression of
short-lived proteins such asMcl-1 that can result in induction of
apoptosis in cancer cells.30 This finding has paved the way for
targeting transcriptional CDKs in addition to cell cycle-regulat-
ing CDKs in cancer therapy. Here we provide evidence that
selective inhibition of CDK9 achieves an exceptionally potent
sensitization to TRAIL-induced apoptosis. Interestingly, the
pan-CDK inhibitors Flavopiridol44–46 and Roscovitine (Selici-
clib)47–49 have previously been shown to synergize with TRAIL.
However, so far, it remained unclear which CDK, inhibited by
these pan-CDK inhibitors, was responsible for these effects.
When combining our result with the fact that Flavopiridol and
Roscovitine also inhibit CDK9, it appears reasonable to
assume that their previously described TRAIL-sensitizing
capacity is likely owed to their CDK9-inhibitory capacity.
Inhibition of certain CDKs can potentially cause toxicity, and
CDK1 inhibition is currently thought to be most problematic in
this respect.50 To avoid potential dose-limiting toxicity, we
devised a novel combinatorial therapy consisting of TRAIL
and SNS-032, an inhibitor targeting CDK9 preferentially over
cell cycle CDKs.33 Importantly, the safety of SNS-032 was
already confirmed in clinical trials51,52 and SNS-032 has been
shown to be more potent in inhibiting transcription than
Flavopiridol and Roscovitine.53 The fact that CDK9 inhibition
was found to be nontoxic in clinical trials implies that normal
cells have possibly developed coping mechanisms that might
not be present in transformed cells. In line with this notion, our
results show that CDK9 inhibition in combination with TRAIL
can selectively kill tumor cells, but not PHH within a significant
therapeutic window. Of note, the concentration at which SNS-
032 effectively sensitizes cancer cells to TRAIL-induced
apoptosis, 300 nM, is commonly reached and sustained in
the plasma of patients.51
Investigating the underlying mechanism of how CDK9
inhibition sensitizes to TRAIL-induced apoptosis revealed that
Mcl-1 downregulation is required, but not sufficient, for TRAIL
sensitization. In addition, CDK9 inhibition-induced suppression
of another short-lived protein, cFlip, was required to achieve
potent TRAIL sensitization. Hence, the synergistic effect of
CDK9 inhibition and TRAIL is due to a dual mechanism:
downregulation of cFlip enables caspase-8 activation at the
DISC and downregulation of Mcl-1 facilitates activation of the
mitochondrial apoptosis pathway for enhanced caspase-9 and,
ultimately, caspase-3 activation. As a consequence, the
combination of TRAIL and CDK9 inhibition is exquisitely
powerful in killing tumor cells with a cFlip-imposed block to
initiator caspase activation at the DISC and an Mcl-1-imposed
block to activation of the mitochondrial apoptosis pathway.
Chemotherapy mostly induces apoptosis by induction of
DNA damage that is sensed by p53.54 However, impairment
of functional p53, either by mutation or loss of expression, is
frequently detected in cancer. Therefore, therapies that
function independently of p53-status are likely to be more
effective than chemotherapy. Importantly, we determined that
CDK9 inhibition sensitizes cancer cells to TRAIL irrespective
of their p53-status, thereby providing a therapeutic option also
for cancers with mutated p53 in which conventional che-
motherapy is largely ineffective. Moreover, the high efficacy of
the newly devised treatment combination was also apparent
in vivo. In an orthotopic lung cancer xenograft model, the
combination of SNS-032 with TRAIL eradicated established
lung tumors after a 4-day treatment cycle. This striking result
provides further support for the high therapeutic potential of
combinations of TRAIL-R agonists with CDK9 inhibitors.
Recent reports on first clinical trials with TRAIL and other
TRAIL-R agonists showed, on the one hand, that these
biotherapeutics were well tolerated but, on the other, that the
clinical activity they exerted, evenwhen combinedwith standard
chemotherapy, was rather limited.6 Cancer cell resistance to
TRAIL-induced apoptosis is likely to be a significant factor in this
outcome, indicating that a TRAIL-comprising therapy will only
be effective when a potent TRAIL sensitizer is applied in
combination with a TRAIL-R agonist. Based on our results, we
propose CDK9 inhibition as an effective means to overcome
TRAIL resistance in a cancer-selective manner.
Materials and Methods
Reagents. Antibodies: a-RNA-Pol II, a-pSer2 and a-pSer5 were purchased
from Covance (Princeton, NJ, USA); a-Caspase-3 and a-cIAP from R&D Systems
(Abingdon, UK); a-cFlip (NF6) and a-Caspase-8 (C15) are available from Enzo
(Exeter, UK); a-PARP was purchased from BD Biosciences (Oxford, UK); a-FADD
was purchased from BD Biosciences (IgG1) or Santa Cruz (Heidelberg,
Germany) (rabbit). a-Caspase-10 and a-Caspase-9 from MBL (Woburn, MA,
USA); a-b-Actin from Sigma (Gillingham, UK) and a-DNA-PK, a-p110a, a-p110b,
a-Bak, a-Bax, a-Mcl-1, a-Bcl-2, a-Bcl-xL, a-XIAP, a-CDK1, a-CDK2, a-CDK4,
a-CDK6, a-CDK7, a-CDK9, a-AKT and a-pAKT(Ser473) from Cell Signaling
(Danvers, MA, USA); a-Bid was obtained from or Cell Signaling (rabbit) or R&D
Systems (goat). HS101 and HS201 were used for surface staining of TRAIL-R1/–
R2 and are available from Enzo (Exeter, UK). Recombinant TRAIL was used as an
isoleucine zipper-tagged version of the extracellular domain of human TRAIL
(izTRAIL) as described previously.39 PIK-75, TGX-221 AS-252424, IC-87144, A66,
BEZ-235, GDC-0941 and SNS-032 were purchased from Selleck Chemicals
(Houston, TX, USA); actinomycin D from Merck Millipore (Darmstadt, Germany);
cycloheximide and crystal violet from Sigma, z-VAD(OMe)-FMK from Abcam
(Cambridge, UK) and D-Luciferin from Caliper Life Science (Waltham, MA, USA).
Cell lines. The human lung adenocarcinoma panel (H460, H522, H322, H441,
Calu-1 and H23) was kindly provided by J Downward and cultured in RPMI
supplemented with 10% FCS. A549-luc cells were purchased from Caliper Life
Science and cultured in RPMI supplemented with 10% FCS. HeLa cells were
cultured in DMEM supplemented with 5% FCS. HCT-116 WT and HCT-116 Bax-/-Bak-/-
were kindly provided by B Vogelstein and R Youle and were cultured in DMEM
supplemented with 10% FCS. PHHs were purchased from Gibco/Invitrogen
(Paisley, UK) and cultured according to the manufacturer’s instructions.
RNA interference. siRNA pools (ON-TARGET plus) containing four different
siRNA sequences targeting each gene of interest were purchased from
Dharmacon/Thermo Scientific (Loughborough, UK). Cells were transfected using
Dharmafect reagent according to the manufacturer’s instructions. Cells were used
for further analysis at 48 or 72 h after transfection. Knockdown efficiency was
assessed by western blot in parallel.
Cell viability and cell death assays. Cell viability was determined using
the Cell Titer Glo assay (Promega, Southampton, UK) according to the
manufacturer’s instructions. As a direct measurement of apoptotic cell death,
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DNA fragmentation was quantified as described before.55 To analyze long-term
survival (clonogenic assay), cells were seeded into six-well plates. The next day,
cells were preincubated with DMSO, PIK-75 or SNS-032 for 1 h before izTRAIL
was added. After 24 h, dead cells were washed away and surviving cells were
cultured for additional 6 days in fresh medium without any treatment. After 7 days,
cells were washed twice with PBS, fixed with 10% formaldehyde in PBS for 30 min
at room temperature and stained with crystal violet (1% in 50% ethanol).
Western blot analysis. Cells were treated as indicated and then lysed in
lysis buffer (30 mM Tris-HCl; pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM KCl, 10%
glycerol, 1% Triton X-100 and 1 complete protease-inhibitor cocktail (Roche,
Burgess Hill, UK)). Proteins were separated by SDS-PAGE (NuPAGE) and
analyzed by western blotting. Membranes were stripped with 50 mM glycine
(pH 2.3) before reprobing with other antibodies.
DISC analysis. We performed ligand affinity precipitations using Flag-tagged
TRAIL in combination with M2 beads (Sigma). Cells were incubated for 1 h at
37 1C in the presence or absence of 1mg/ml Flag-TRAIL. For the precipitation of
the non-stimulated receptors, Flag-TRAIL was added to the lysates prepared from
non-stimulated cells. Precipitates were prepared as described previously.56
TRAIL-R surface staining. Cells were detached using Accutase (Sigma) and
counted. Cells (2 105) were incubated with 10mg/ml anti-TRAIL-R1 (HS101) or
anti-TRAIL-R2 (HS201) or IgG1 isotype control antibody in 2% BSA in 100ml PBS
(BSA/PBS) for 30 min on ice. Cells were washed twice with ice-cold BSA/PBS before
incubation with secondary goat–anti-mouse-APC (BioLegend, London, UK) at a
dilution of 1:200 in BSA/PBS for 20 min on ice. Cells were washed three times in ice-
cold BSA/PBS and surface expression was assessed by flow cytometry.
Overexpression of cFlip and Mcl-1. HeLa cells were transfected with
control, PEGZ-cFlip, pEF 3xFLAG-hMcl-1 or both using Lipofectamine LTX
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions. Cells were
left untreated for 24 h before any treatment to ensure efficient expression of the
respective protein. Efficient expression of the respective protein was controlled by
SDS-PAGE and subsequent western blot. Furthermore, cells were transfected with a
GFP-containing plasmid and transfection efficiency was quantified by flow cytometry.
Determination of AST values. Supernatant (30 ml) of treated PHHs was
used to determine AST levels using a Reflovet Analyzer (Roche) and Reflotron
GOT test strips according to the manufacturer’s instructions.
Caspase-cleaved CK 18-ELISA. Supernatant (50 ml) of treated PHHs was
used in the M30 Apoptosense ELISA (Peviva, Bromma, Sweden) according to the
manufacturer’s instructions.
High-Throughput kinase selectivity profiling (Kinomescan).
High-throughput kinase selectivity profiling assay (Kinomescan, DiscoveRx,
Fremont, CA, USA) was used to determine the promiscuity of PIK-75 as a
kinase inhibitor. The capacity of PIK-75 to bind to a panel of 451 human kinases
was determined by analyzing the binding interaction (%) compared with DMSO
(¼ 100%). We chose to use PIK-75 at 200 nM in this screen because this was
twice the concentration of this agent required to sensitize cancer cells to TRAIL.
Hits were visualized using the TREEspot visualization tool provided by DiscoveRx.
Kinases were considered hits if their activity was inhibited by 490% leaving
o10% remaining activity.
RNA analysis by RT-PCR. RNA was extracted using the RNeasy Kit
(Qiagen, Manchester, UK) and treated with the TURBO DNA-free Kit (Ambion,
Paisley, UK) according to the manufacturer’s instructions. cDNA was generated
using the RevertAid H Minus Strand cDNA Synthesis Kit (Thermo Scientific,
Loughborough, UK) and used in combination with the FastStart Universal
ProbeLibrary Mastermix (Roche) for the RT-PCR. Quantification of gene products
was performed using the Eppendorf Mastercycler. When fold changes are shown,
the gene product was normalized to GAPDH as a housekeeping gene and were
calculated using the method described by Pfaffl et al.57
Primers for RT-PCR. Primers and probe combinations were determined
using the Universal ProbeLibrary Design Center (Roche) and are as follows.
cFLIP(s) forward: 50–TTGGAAATTGTTCCATGTGATT-30
cFLIP(s) reverse: 50-GCAACAAGAAAGGGCTAAACA-30
cFLIP(s) Essay Universal ProbeLibrary Number: 34
cFLIP(l) forward: 50-GCTCACCATCCCTGTACCTG-30
cFLIP(l) reverse: 50-CAGGAGTGGGCGTTTTCTT-30
cFLIP(l) Essay Universal ProbeLibrary Number: 14
CDK9 forward: 50-TTCGGGGAGGTGTTCAAG-30
CDK9 reverse: 50-ATCTCCCGCAAGGCTGTAAT-30
CDK9 Essay Universal ProbeLibrary Number: 21
MCL-1 forward: 50-AAGCCAATGGGCAGGTCT-30
MCL-1 reverse: 50-TGTCCAGTTTCCGAAGCAT-30
MCL-1 Essay Universal ProbeLibrary Number: 49
GAPDH forward: 50-AGCCACATCGCTCAGACAC-30
GAPDH reverse: 50-GCCCAATACGACCAAATCC-30
GAPDH Essay Universal ProbeLibrary Number: 60
Orthotopic lung cancer xenograft. Female Fox Chase SCID Beige Mice
(6–12 week old; Charles River, Germany) were injected with 2 106 A549-luc
cells via the lateral tail vein. After 1 week, all mice were imaged for
bioluminescence using the Ivis Spectrum (Caliper Life Science). Photons
per second (Photon Flux) were quantified using the Ivis Spectrum software. Mice
with established tumor burden were included in the study and randomized into the
treatment groups (eight mice/group). Subsequently, mice were treated for 4
consecutive days with daily i.p. injections of 600 mg SNS-032 (30 mg/kg) and/or
100mg izTRAIL or 200 ml buffer as control. After 3 weeks, tumor burden was
quantified by bioluminescence imaging. For preparation of lung tissue sections,
mice were killed according to Guidance on Operation of Animals (Scientific
Procedures) Act 1986. Lungs were removed, fixed in 10% formalin for 1 week and
then transferred to 70% ethanol. Paraffin embedding, preparation of sections and
H&E stainings were performed as part of a histological staining service at the
National Heart & Lung Institute. H&E stainings were examined and quantified by
an experienced pathologist (MAE-B) who was blinded to the study. Tumor burden
was quantified as percentage of tumor tissue in the lung. SCID beige mice were
maintained in individually ventilated cages, received autoclaved food, water and
bedding according to the institutional guidelines under a UK Home Office project
license. The required risk assessments were obtained for this study.
Statistical analysis. Data were analyzed using GraphPad Prism 6 software
(GraphPad Software). Statistical significance between groups was determined
using Student’s t-test. Significant P-values are denoted as *Po0.05; **Po0.01;
***Po0.001.
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